|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li S, de Camargo Correia GS, Wang J,
Manochakian R, Zhao Y and Lou Y: Emerging targeted therapies in
advanced non-small-cell lung cancer. Cancers (Basel). 15:28992023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan AC and Tan DSW: Targeted therapies for
lung cancer patients with oncogenic driver molecular alterations. J
Clin Oncol. 40:611–625. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alexander M, Kim SY and Cheng H: Update
2020: Management of non-small cell lung cancer. Lung. 198:897–907.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jurišić V, Obradovic J, Pavlović S and
Djordjevic N: Epidermal growth factor receptor gene in
non-small-cell lung cancer: The importance of promoter polymorphism
investigation. Anal Cell Pathol (Amst). 2018:61921872018.PubMed/NCBI
|
|
6
|
Jurisic V, Obradovic J, Nikolic N, Javorac
J, Perin B and Milasin J: Analyses of P16INK4a gene
promoter methylation relative to molecular, demographic and
clinical parameters characteristics in non-small cell lung cancer
patients: A pilot study. Mol Biol Rep. 50:971–979. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun R, Hou Z, Zhang Y and Jiang B: Drug
resistance mechanisms and progress in the treatment of EGFR-mutated
lung adenocarcinoma. Oncol Lett. 24:4082022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kirschmann DA, Seftor EA, Hardy KM, Seftor
RE and Hendrix MJ: Molecular pathways: Vasculogenic mimicry in
tumor cells: Diagnostic and therapeutic implications. Clin Cancer
Res. 18:2726–2732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z
and Zhou Q: Tumour vasculogenic mimicry is associated with poor
prognosis of human cancer patients: A systemic review and
meta-analysis. Eur J Cancer. 49:3914–3923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hendrix MJ, Seftor EA, Hess AR and Seftor
RE: Vasculogenic mimicry and tumour-cell plasticity: Lessons from
melanoma. Nat Rev Cancer. 3:411–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van der Schaft DW, Seftor RE, Seftor EA,
Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW and
Hendrix MJ: Effects of angiogenesis inhibitors on vascular network
formation by human endothelial and melanoma cells. J Natl Cancer
Inst. 96:1473–1477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Angara K, Rashid MH, Shankar A, Ara R,
Iskander A, Borin TF, Jain M, Achyut BR and Arbab AS: Vascular
mimicry in glioblastoma following anti-angiogenic and anti-20-HETE
therapies. Histol Histopathol. 32:917–928. 2017.PubMed/NCBI
|
|
13
|
Song H, Ci H, Xu J, Xu Z, Zhang Y, Wang Y,
Wu S and Tao Y: Vasculogenic mimicry and expression of slug and
vimentin correlate with metastasis and prognosis in non-small cell
lung cancer. Int J Clin Exp Pathol. 11:2749–2758. 2018.PubMed/NCBI
|
|
14
|
Ci H, Xu Z, Xu J, Wang Y and Wu S:
Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and
their correlation with vasculogenic mimicry. Medicine (Baltimore).
97:e122932018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou X, Gu R, Han X, Wu G and Liu J:
Cyclin-dependent kinase 5 controls vasculogenic mimicry formation
in non-small cell lung cancer via the FAK-AKT signaling pathway.
Biochem Biophys Res Commun. 492:447–452. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naeem A, Dakshanamurthy S, Walthieu H,
Parasido E, Avantaggiati M, Tricoli L, Kumar D, Lee RJ, Feldman A,
Noon MS, et al: Predicting new drug indications for prostate
cancer: The integration of an in silico proteochemometric network
pharmacology platform with patient-derived primary prostate cells.
Prostate. 80:1233–1243. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dalwadi SM, Hunt A, Bonnen MD and Ghebre
YT: Computational approaches for drug repurposing in oncology:
Untapped opportunity for high value innovation. Front Oncol.
13:11982842023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu H, Huang D, Zhou H, Sima X, Wu Z, Sun
Y, Wang L, Ruan Y, Wu Q, Wu F, et al: Metformin: A promising drug
for human cancers. Oncol Lett. 24:2042022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pantziarka P, Pirmohamed M and Mirza N:
New uses for old drugs. BMJ. 361:k27012018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Batty M, Pugh R, Rathinam I, Simmonds J,
Walker E, Forbes A, Anoopkumar-Dukie S, McDermott CM, Spencer B,
Christie D and Chess-Williams R: The role of α1-Adrenoceptor
antagonists in the treatment of prostate and other cancers. Int J
Mol Sci. 17:13392016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forbes A, Anoopkumar-Dukie S,
Chess-Williams R and McDermott C: Relative cytotoxic potencies and
cell death mechanisms of α1-adrenoceptor antagonists in prostate
cancer cell lines. Prostate. 76:757–766. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bilbro J, Mart M and Kyprianou N:
Therapeutic value of quinazoline-based compounds in prostate
cancer. Anticancer Res. 33:4695–4700. 2013.PubMed/NCBI
|
|
23
|
Keledjian K, Garrison JB and Kyprianou N:
Doxazosin inhibits human vascular endothelial cell adhesion,
migration, and invasion. J Cell Biochem. 94:374–388. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park MS, Kim BR, Dong SM, Lee SH, Kim DY
and Rho SB: The antihypertension drug doxazosin inhibits tumor
growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling
and VEGF and HIF-1α expression. Oncotarget. 5:4935–4944. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scherbakov AM, Vorontsova SK, Khamidullina
AI, Mrdjanovic J, Andreeva OE, Bogdanov FB, Salnikova DI, Jurisic
V, Zavarzin IV and Shirinian VZ: Novel pentacyclic derivatives and
benzylidenes of the progesterone series cause anti-estrogenic and
antiproliferative effects and induce apoptosis in breast cancer
cells. Invest New Drugs. 41:142–152. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jurisic V, Bogdanovic G, Kojic V, Jakimov
D and Srdic T: Effect of TNF-alpha on Raji cells at different
cellular levels estimated by various methods. Ann Hematol.
85:86–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Skehan P, Storeng R, Scudiero D, Monks A,
McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jurisic V, Srdic-Rajic T, Konjevic G,
Bogdanovic G and Colic M: TNF-α induced apoptosis is accompanied
with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr
Biol. 239:115–122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaifer CA, Huang J and Lin PC:
Glioblastoma cells incorporate into tumor vasculature and
contribute to vascular radioresistance. Int J Cancer.
127:2063–2075. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Racordon D, Valdivia A, Mingo G, Erices R,
Aravena R, Santoro F, Bravo ML, Ramirez C, Gonzalez P, Sandoval A,
et al: Structural and functional identification of vasculogenic
mimicry in vitro. Sci Rep. 7:69852017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jurisic V: Multiomic analysis of cytokines
in immuno-oncology. Expert Rev Proteomics. 17:663–674. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cabral-Pacheco GA, Garza-Veloz I,
Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA,
Guerrero-Rodriguez JF, Martinez-Avila N and Martinez-Fierro ML: The
roles of matrix metalloproteinases and their inhibitors in human
diseases. Int J Mol Sci. 21:97392020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vincent J, Elliott HL, Meredith PA and
Reid JL: Doxazosin, an alpha 1-adrenoceptor antagonist:
Pharmacokinetics and concentration-effect relationships in man. Br
J Clin Pharmacol. 15:719–725. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Franco P, Camerino I, Merlino F, D'Angelo
M, Cimmino A, Carotenuto A, Colucci-D'Amato L and Stoppelli MP:
αV–Integrin-Dependent inhibition of glioblastoma cell migration,
invasion and vasculogenic mimicry by the uPAcyclin decapeptide.
Cancers (Basel). 15:47752023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qin Y, Zhao W, Cai Z, Wang Q, Gao J, Ci H,
Feng Z and Ma L: The biomarker like the correlation between
vasculogenic mimicry, vascular endothelial cadherin,
sex-determiningregion on Y-Box transcription factor 17, and cyclin
D1 in oesophageal squamous cell carcinoma. J Oncol.
2022:89155032022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Tan Y, Liu S, Yin H, Duan J, Fan
L, Zhao X and Jiang B: Implications of Withaferin A for the
metastatic potential and drug resistance in hepatocellular
carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech
Methods. 33:47–55. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Delgado-Bellido D, Garcia-Diaz A and
Oliver FJ: Co-immunoprecipitation of protein complexes from
different subcellular compartments in vasculogenic mimicry studies.
Methods Mol Biol. 2514:61–72. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Delgado-Bellido D, Oliver FJ, Vargas
Padilla MV, Lobo-Selma L, Chacón-Barrado A, Díaz-Martin J and de
Álava E: VE-Cadherin in cancer-associated angiogenesis: A deceptive
strategy of blood vessel formation. Int J Mol Sci. 24:93432023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Winkler J, Abisoye-Ogunniyan A, Metcalf KJ
and Werb Z: Concepts of extracellular matrix remodelling in tumour
progression and metastasis. Nat Commun. 11:51202020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seftor RE, Seftor EA, Koshikawa N, Meltzer
PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and
Hendrix MJ: Cooperative interactions of laminin 5 gamma2 chain,
matrix metalloproteinase-2, and membrane
type-1-matrix/metalloproteinase are required for mimicry of
embryonic vasculogenesis by aggressive melanoma. Cancer Res.
61:6322–6327. 2001.PubMed/NCBI
|
|
42
|
Liu Q, Qiao L, Liang N, Xie J and Zhang J,
Deng G, Luo H and Zhang J: The relationship between vasculogenic
mimicry and epithelial-mesenchymal transitions. J Cell Mol Med.
20:1761–1769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Valdivia A, Mingo G, Aldana V, Pinto MP,
Ramirez M, Retamal C, Gonzalez A, Nualart F, Corvalan AH and Owen
GI: Fact or fiction, it is time for a verdict on vasculogenic
mimicry? Front Oncol. 9:6802019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin SC, Chueh SC, Hsiao CJ, Li TK, Chen
TH, Liao CH, Lyu PC and Guh JH: Prazosin displays anticancer
activity against human prostate cancers: Targeting DNA and cell
cycle. Neoplasia. 9:830–839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Arencibia JM, Del Rio M, Bonnin A, Lopes
R, Lemoine NR and López-Barahona M: Doxazosin induces apoptosis in
LNCaP prostate cancer cell line through DNA binding and
DNA-dependent protein kinase down-regulation. Int J Oncol.
27:1617–1623. 2005.PubMed/NCBI
|
|
47
|
Partin JV, Anglin IE and Kyprianou N:
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate
cancer cell apoptosis via TGF-beta signalling and I kappa B alpha
induction. Br J Cancer. 88:1615–1621. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Treps L, Le Guelte A and Gavard J:
Emerging roles of Semaphorins in the regulation of epithelial and
endothelial junctions. Tissue Barriers. 1:e232722013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hendrix MJ, Seftor EA, Meltzer PS, Gardner
LM, Hess AR, Kirschmann DA, Schatteman GC and Seftor RE: Expression
and functional significance of VE-cadherin in aggressive human
melanoma cells: Role in vasculogenic mimicry. Proc Natl Acad Sci
USA. 98:8018–8023. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shuai Q, Cao L, Qin Z, Zhang Y, Gu Z and
Yang J: VE-cadherin fusion protein substrate enhanced the
vasculogenic mimicry capability of hepatocellular carcinoma cells.
J Mater Chem B. 8:1699–1712. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Maroufi NF, Rashidi M, Vahedian V,
Jahanbazi R, Mostafaei S, Akbarzadeh M, Kazemzadeh H, Nejabati HR,
Isazadeh A, Rashidi MR and Nouri M: Effect of Apatinib plus
melatonin on vasculogenic mimicry formation by cancer stem cells
from breast cancer cell line. Breast Cancer. 29:260–273. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Frank NY, Schatton T, Kim S, Zhan Q,
Wilson BJ, Ma J, Saab KR, Osherov V, Widlund HR, Gasser M, et al:
VEGFR-1 expressed by malignant melanoma-initiating cells is
required for tumor growth. Cancer Res. 71:1474–1485. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang JY, Sun T, Zhao XL, Zhang SW, Zhang
DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional
significance of VEGF-a in human ovarian carcinoma: Role in
vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vartanian A, Stepanova E, Grigorieva I,
Solomko E, Baryshnikov A and Lichinitser M: VEGFR1 and PKCα
signaling control melanoma vasculogenic mimicry in a VEGFR2
kinase-independent manner. Melanoma Res. 21:91–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu X, Zong Y, Gao Y, Sun X, Zhao H, Luo W
and Jia S: VEGF induce vasculogenic mimicry of choroidal melanoma
through the PI3k signal pathway. Biomed Res Int. 2019:39091022019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cheng N, Brantley D, Fang WB, Liu H,
Fanslow W, Cerretti DP, Bussell KN, Reith A, Jackson D and Chen J:
Inhibition of VEGF-dependent multistage carcinogenesis by soluble
EphA receptors. Neoplasia. 5:445–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brantley-Sieders DM, Fang WB, Hwang Y,
Hicks D and Chen J: Ephrin-A1 facilitates mammary tumor metastasis
through an angiogenesis-dependent mechanism mediated by EphA
receptor and vascular endothelial growth factor in mice. Cancer
Res. 66:10315–10324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Guan YY, Luan X, Lu Q, Liu YR, Sun P, Zhao
M, Chen HZ and Fang C: Natural products with antiangiogenic and
antivasculogenic mimicry activity. Mini Rev Med Chem. 16:1290–1302.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Han H, Du L, Cao Z, Zhang B and Zhou Q:
Triptonide potently suppresses pancreatic cancer cell-mediated
vasculogenic mimicry by inhibiting expression of VE-cadherin and
chemokine ligand 2 genes. Eur J Pharmacol. 818:593–603. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gong FL, Wang L, Yu LG, Dang YF, Jiang XN,
Zhao L and Guo XL: DHPAC, a novel microtubule depolymerizing agent,
suppresses angiogenesis and vasculogenic mimicry formation of human
non-small cell lung cancer. J Cell Biochem. 121:4756–4771. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Margaryan NV, Strizzi L, Abbott DE, Seftor
EA, Rao MS, Hendrix MJ and Hess AR: EphA2 as a promoter of melanoma
tumorigenicity. Cancer Biol Ther. 8:279–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Incerti M, Russo S, Corrado M, Giorgio C,
Ballabeni V, Chiodelli P, Rusnati M, Scalvini L, Callegari D,
Castelli R, et al: Optimization of EphA2 antagonists based on a
lithocholic acid core led to the identification of UniPR505, a new
3α-carbamoyloxy derivative with antiangiogenetic properties. Eur J
Med Chem. 189:1120832020. View Article : Google Scholar : PubMed/NCBI
|
